Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging
Citation
Mikula, Hannes, Shawn Stapleton, Rainer H. Kohler, Claudio Vinegoni, and Ralph Weissleder. 2017. “Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging.” Theranostics 7 (5): 1257-1265. doi:10.7150/thno.18238. http://dx.doi.org/10.7150/thno.18238.Abstract
Herein we describe fluorescent derivatives of vemurafenib to probe therapeutic BRAF inhibition in live cells and in vivo. The compounds were evaluated and compared by determining target binding, inhibition of mutant BRAF melanoma cell lines and live cell imaging. We show that vemurafenib-BODIPY is a superior imaging drug to visualize the targets of vemurafenib in live cells and in vivo in non-resistant and resistant melanoma tumors.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399591/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630440
Collections
- HMS Scholarly Articles [18278]
Contact administrator regarding this item (to report mistakes or request changes)